Patricia Young, MD
Medical Oncology · Los Angeles, CANPI 1285957589
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $199 of the $254 with a category attached, or 78.4%. 6 manufacturers reported payments, led by Alnylam Pharmaceuticals Inc. at 53.2% of the total. Reporting peaked in 2019 at $135 and has fallen 81.6% since, to $25 in 2025. That places this record below the midpoint for medical oncology clinicians in CA, where the typical reported total is $4,042.
Across 7 payments — averaging $36.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alnylam Pharmaceuticals Inc.$135
- Takeda Pharmaceuticals U.S.A., Inc.$33
- Beigene USA, Inc.$25
- Beone Medicines USA, Inc.$25
- Johnson & Johnson$24
- Gilead$12
Across 124 payments — averaging $24,693 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$1.3M
- Novartis$624K
- Servier Bioinnovation$587K
- Takeda Pharmaceuticals U.S.A., Inc.$216K
- Eli Lilly$148K
- Genentech, Inc.$115K
- plus $42K from 4 others
What the payments were for
- Food & beverage$19978%
- Education$5522%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 2 | $135 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $33 |
| Beigene USA, Inc. | 1 | $25 |
| Beone Medicines USA, Inc. | 1 | $25 |
| Johnson & Johnson | 1 | $24 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ONPATTRO$125
How this compares
$254 in reported general payments places this provider in the 20th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OnuregAzacitidine | 18 | $458,047 |
| Lenalidomide | 31 | $456,030 |
| VenclextaVenetoclax | 23 | $296,897 |
| ImbruvicaIbrutinib | 13 | $248,751 |
| BrukinsaZanubrutinib | 14 | $165,093 |
| EliquisApixaban | 27 | $24,400 |
| Atovaquone | 14 | $8,341 |
| XareltoRivaroxaban | 12 | $6,464 |
| SavaysaEdoxaban Tosylate | 13 | $4,882 |
| Acyclovir | 67 | $1,652 |
| Hydroxyurea | 15 | $467 |
| Pantoprazole Sodium | 11 | $194 |
| Nystatin | 11 | $144 |
| Prednisone | 42 | $102 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 17 | $79 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Beigene USA, Inc.Brukinsa | $25 | $165,09314 claims |
| Johnson & JohnsonXarelto | $24 | $6,46412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 379 medical oncology providers in California.
Other medical oncology in Los Angeles
- Stephen LiuLos Angeles$750K
- Jacek PinskiLos Angeles$672K
- Mark AgulnikLos Angeles$303K
- Heinz-Josef LenzLos Angeles$185K
- Syma IqbalLos Angeles$178K
- Anthony El-KhoueiryLos Angeles$156K
- David QuinnLos Angeles$134K
- David TranLos Angeles$128K
- Afsaneh BarziLos Angeles$107K
- Stephen SherwinSan Francisco$6.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.